From the Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
From the Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona
AJNR Am J Neuroradiol. 2023 Aug;44(8):939-942. doi: 10.3174/ajnr.A7936. Epub 2023 Jul 20.
Nickel is used in many cerebral endovascular treatment devices. However, nickel hypersensitivity is the most common metal allergy, and the relative risk of treatment in these patients is unknown. This retrospective analysis identified patients with nickel or metal allergies who underwent cerebral endovascular treatment with nickel-containing devices. Seven patients with nickel and/or other metal allergies underwent treatment with 9 nickel-containing devices. None experienced periprocedural complications. No patient received treatment with corticosteroids or antihistamines. At a mean clinical follow-up for all patients of 22.8 months (range, 10.5-38.0 months), no patients had symptoms attributable to nickel allergic reactions. The mean radiographic follow-up for all patients at 18.4 months (range, 2.5-37.5 months) showed successful treatment of the targeted vascular pathologies, with no evidence of in-stent stenosis or other allergic or hypersensitivity sequelae. The treatment of cerebrovascular lesions with a nickel-containing device resulted in no adverse outcomes among these patients and was safe and effective.
镍被用于许多脑血管内治疗设备中。然而,镍过敏是最常见的金属过敏,这些患者的治疗相对风险尚不清楚。本回顾性分析确定了镍或金属过敏的患者,他们接受了含镍设备的脑血管内治疗。7 名镍和/或其他金属过敏的患者接受了 9 种含镍设备的治疗。无患者发生围手术期并发症。无患者接受皮质类固醇或抗组胺药物治疗。在所有患者的平均临床随访 22.8 个月(范围为 10.5-38.0 个月)中,无患者出现归因于镍过敏反应的症状。所有患者的平均影像学随访时间为 18.4 个月(范围为 2.5-37.5 个月),显示靶向血管病变的治疗成功,支架内狭窄或其他过敏或超敏反应后遗症均无证据。在这些患者中,使用含镍装置治疗脑血管病变没有不良结果,并且是安全有效的。